Latest news with #Dana-Farber
Time Business News
6 days ago
- Health
- Time Business News
Cutting-Edge Technologies in Lung Cancer Testing
A lung cancer diagnostic test is a medical procedure that is used to detect the presence of cancer cells in the lungs. These tests include imaging techniques (such as X-ray and CT scan), tissue biopsy, spit cytology, and advanced methods such as liquid biopsy and molecular tests to identify the type and phase of cancer. The growth of lung cancer diagnostic test market is inspired by increasing demand for personalized treatment based on the government's initiative for cancer screening and genetic profiling. Key Growth Drivers and Opportunities Rising Demand for Personalized Treatment: Increasing demand for personal treatment is significantly increasing the development of lung cancer diagnostic test market, as it requires accurate and wide diagnostic equipment to identify specific genetic mutations, biomarkers and cancer sub-types. Personal remedies, such as targeted drugs and immunotherapy, have greatly rely on accurate clinical consequences for tailor treatment schemes for individual patients. This has increased adopting advanced clinical techniques such as liquid biopsy, next generation sequencing (NGS), and molecular testing. Since healthcare provider and patients want more effective, less aggressive and sewn treatment approaches, the demand for high-collective clinical trials continues to promote market expansion. Challenges Lung cancer diagnostic test market faces many borders that can obstruct its growth and access. High costs associated with advanced clinical technologies such as PET scans, liquid biopsy and next generation sequencing make them less cheap in countries with less and moderate income. Additionally, delayed diagnosis in delayed diagnosis due to limited infrastructure, lack of efficient health professionals, and lack of awareness in the reduction of available tests. In some clinical methods, false positive or negative can also cause incorrect diagnosis, affecting the consequences of treatment. Regulatory barriers and variability in testing accuracy further limited widely adopting innovative clinical equipment in clinical settings. Innovation and Expansion An Innovative Lung Cancer Screening Trial for High-Risk Individuals has been launched by the EQUAL Study In May 2025, Researchers at the Dana-Farber Cancer Institute have begun testing a new, in-house blood test in an effort to screen for lung cancer and identify those who are at a higher risk of developing the disease even if they have never used tobacco. As lung cancer is becoming more common in younger people and among Asian or Hispanic/Latinx people who have never used tobacco, the team, led by the principal investigator and thoracic oncologist, associate director of Dana-Farber's Cancer Care Equity Program, designed the study. Epidermal growth factor receptor (EGFR) gene mutations can be common in the Asian and Hispanic/Latinx populations, which is the subject of the EQUAL (EGFR ctDNA Quantitative Assessment for Lung Cancer screening in Asian and Latinx populations) study. Possessing this mutation increases the risk of lung cancer because EGFR type mutations are linked to the illness. Additionally, the number of cancer diagnoses among Asian or Hispanic/Latinx individuals is increasing at a faster rate. The LuNGS Alliance has launched a Free NGS Biomarker Screening Program for Lung Cancer In March 2025, For patients with lung cancer throughout India, the Cancer Research and Statistics Foundation (CRSF)-led LuNGS Alliance has announced free lung NGS biomarker testing. AstraZeneca, Pfizer, and Roche support this program, and 4baseCare is the official lab partner. The initiative's goal is to raise awareness of precision oncology as a crucial, easily accessible, and reasonably priced therapy option for lung cancer. 4baseCare's TARGT First Solid test provides a thorough examination of 72 frequently mutated genes, revealing actionable biomarkers that allow for individualized treatment regimens based on each patient's own genetic profile. The test finds mutations that match FDA and NCCN-approved medications, enabling oncologists to offer more individualized, potent treatments that can greatly enhance patient outcomes. Inventive Sparks, Expanding Markets The key players operating in the lung cancer diagnostic test market includes Abbott, Illumina, Inc., Thermo Fischer Scientific, QIAGEN, Quest Diagnostics Incorporated, NeoGenomics, NanoString, Myriad Genetics Inc., F. Hoffmann-La Roche Ltd, Danaher, Agilent Technologies, Inc., AstraZeneca, Sanofi, and Janssen Pharmaceuticals, Inc. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
Boston Globe
17-06-2025
- Entertainment
- Boston Globe
Rich Shertenlieb announces fund-raising venture after wife's cancer diagnosis
Each video and podcast will conclude with a barcode or a call to action to donate to the Pan-Mass Challenge bicycle ride, Dana-Farber's biggest fund-raiser. As Shertenlieb's longtime listeners know, cancer research is a deeply personal cause for his family. Shertenlieb's wife, Mary, is a three-time cancer survivor. She was diagnosed with a recurrence of leukemia in November, 12 years after her initial diagnosis. Advertisement 'The people at Dana-Farber Cancer Center saved my wife's life, are attempting to save it again, so this is the only way I know how to give back,' said Shertenlieb in an email. In his video announcing the new venture, Shertenlieb — who said he will be participating in the Pan-Mass Challenge this year — elaborated briefly on what his wife faces. 'She is one of the toughest people on the planet,' he said. He said he can't put into words his appreciation for how important Dana-Farber has been to his wife and family. 'I don't know how you pay back somebody for saving the life of somebody you love,' he said, 'but this is how I'm going to try.' Chad Finn can be reached at
Time Out
02-06-2025
- Entertainment
- Time Out
Scooper Bowl
Courtesy: ScooperBowl The nation's largest all-you-can-eat ice cream festival returns to City Hall Plaza from June 3-5, as the Scooper Bowl raises money to warm your heart while dishing out more than 10 tons of ice cream, gelato, frozen yogurt and sorbet from 12-8pm. This three-day long family-friendly event has something for everyone and features frozen treats from favorite local and national brands, and serves as a prominent fundraiser for the Jimmy Fund to benefit cancer research at Dana-Farber. Not only is it all-you-can eat, but you can vote for your favorite flavor. By entering your email address you agree to our Terms of Use and Privacy Policy and consent to receive emails from Time Out about news, events, offers and partner promotions. 🙌 Awesome, you're subscribed! Thanks for subscribing! Look out for your first newsletter in your inbox soon! Discover Time Out original video
CBS News
22-04-2025
- Sport
- CBS News
Runners say the Boston Marathon is a "once in a lifetime experience"
Around 32,000 people ran the Boston Marathon on Monday, but the race is much more than just miles. It's about the people and why they are running. At the end of the 26.2-mile journey, there are hugs, selfies, wobbling, and tears of joy. "This by far is my favorite marathon. Nothing compares to Boston," says 69-year-old Nancy Smith from Virginia. She knows the course better than most. "It's very special to me. It's my 25 consecutive Boston Marathon and also my 10th year running on Dana-Farber, so I have the best of both worlds." Nancy received her medal from Bonnie Yezukevich, who has spent the last ten years volunteering at the marathon. "People just share a moment with you. Sometimes they want a hug and sometimes they want a high five, but they are always real excited and they always thank us, and they don't have to thank us; we would be here anyway. We love it," Yezukevich said. Katie Meyer from Cambridge said that Monday's weather was perfect for running her 12th Boston Marathon. "But every year it's amazing! Just really happy I'm from Boston," said Katie Meyer. "I feel so strong. That's crazy because I feel strong and my body feels so strong, so good. I am so happy and so excited," said Jeimey Vindel, who just finished her first marathon. Her mother was beaming with pride at the challenge her daughter completed. "It was amazing. You have all the feelings in your heart," Ana Vindel. Jackson Murray is a junior at Boston College and said running his first marathon was "unbelievable." "It's a once in a life time feeling," Murray said. "When I turned onto the Newton hills, I got a rush through my body that I'd never felt before in my life, and then that happened again at BC." While for some runners this may be their first Boston Marathon, it won't be their last marathon of the week. "I feel tired. I feel excited and happy. When I crossed the finish line, I was crying very serious tears of joy because there's that time cut off, and I made it by 5:25, so I did it," Pilar Arthur Snead explained. Snead just wrapped up her first Boston Marathon and will now head to complete the London Marathon this weekend. She is on a journey to complete all the major marathons. "You know what. Boston shows up for runners. I was so impressed with everybody out on the course," Snead said.
Yahoo
18-04-2025
- Health
- Yahoo
Running for a reason
MT. PLEASANT, S.C. (WCBD) – 'I had a seven-month-old baby, I was working at Motley Rice here in Mt. Pleasant and I received a call from a doctor at MUSC and they said come down now,' said Sara Couch. In 2021 at 34 years old, Couch was told she had stage three cervical cancer. 'It was very scary, I was in a little room and the doctor came in and seven residents came in and I was like, this is not a good sign.' At the time, the doctors were worried it may be stage four cancer, which is a terminal diagnosis. Luckily for Couch it hadn't spread that far and she is now in remission Sara began running after she finished treatment. 'It was just recommended as a good way to help reduce occurrence and mortality risks to get your strength back, your immune system.' On Monday she will run in the Boston Marathon as part of the Dana-Farber team. After her initial diagnosis, Sara received a second opinion from the cancer institute in Boston. Dana-Farber also funded an immuno-therapy drug that was helpful to Couch as well. 'Every time I run I just feel such immense gratitude to even have the ability to be that healthy because when I finished treatment I was in a wheelchair. I started walking five minutes, then I would walk ten minutes.' Being able to combine something she's so appreciative for, with now being able to help others is very personal for Sara. 'I was gifted so much, right, I was gifted family that helped, an employer that helped, amazing amazing medical care from a lot of doctors and a lot of institutions that came together and that's why I'm here.' Couch said. 'And it took everyone, so if I can give back just a little bit to someone else to have that chance with their daughter, that's what I want to do.' From barely being able to walk for five minutes, Couch is now gearing up to run 26 miles. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
